The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO)

The study of Intravitreal aflibercept with treat and extend regimen for macular edema with branch retinal vein occlusion (BRVO) - The study of aflibercept with treat and extend regimen for BRVO

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023200

Enrollment

Registered

2016-09-01

Start date

2016-10-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Branch retinal vein occlusion

Interventions

Eylea (aflibercept)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. more than 20 years-old, treatment-naive BRVO 2. Visual acuity : 0.1-0.5 3. The duration of BRVO < 3 months 4. outpatients

Exclusion criteria

Exclusion criteria: 1. History of vitrectomy or glaucoma surgery 2. Other disorders such as DME, CRVO or idiopathic macular telangiectasia 3. Poor control hypertension (systolic pressure >180mmHg, diastolic pressure >100mmHg) 4. Concomitant conditions/diseases including uncontrolled glaucoma and intraocular inflammation 5. Patients who the doctor in charge judges are ineligible for the study

Design outcomes

Primary

Measure	Time frame
Change of BCVA from baseline to 12M	—

Secondary

Measure	Time frame
1. Change of OCT from baseline at 12M 2. The number of injections between 12M from baseline 3. Safety	—

Countries

Japan

Contacts

Public ContactMasaaki Saito

Akita University Department of Ophthalmology

masaaki@med.akita-u.ac.jp018-834-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026